This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
BNO Aktienübersicht
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bionomics Limited Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.074 |
| 52 Week Low | AU$0.009 |
| Beta | 2.13 |
| 1 Month Change | -16.67% |
| 3 Month Change | -52.38% |
| 1 Year Change | -81.13% |
| 3 Year Change | -92.86% |
| 5 Year Change | -98.10% |
| Change since IPO | -98.48% |
Aktuelle Nachrichten und Updates
Recent updates
Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?
Jun 14
Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?
Feb 23Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?
Sep 14Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth
Nov 15Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?
Dec 30Aktionärsrenditen
| BNO | AU Biotechs | AU Markt | |
|---|---|---|---|
| 7D | 0% | -0.1% | -2.0% |
| 1Y | -81.1% | 2.7% | 6.1% |
Rendite im Vergleich zur Industrie: BNO underperformed the Australian Biotechs industry which returned -9.1% over the past year.
Rendite vs. Markt: BNO underperformed the Australian Market which returned 1.8% over the past year.
Preisvolatilität
| BNO volatility | |
|---|---|
| BNO Average Weekly Movement | 24.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 16.1% |
| 10% least volatile stocks in AU Market | 3.2% |
Stabiler Aktienkurs: BNO's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: BNO's weekly volatility has increased from 18% to 24% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited's Grundlagenzusammenfassung
| BNO grundlegende Statistiken | |
|---|---|
| Marktanteil | AU$14.69m |
| Gewinn(TTM) | -AU$24.91m |
| Umsatz(TTM) | AU$6.02m |
2.4x
Kurs-Umsatz-Verhältnis-0.6x
Kurs-Gewinn-VerhältnisIst BNO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BNO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | AU$6.02m |
| Kosten der Einnahmen | AU$19.80m |
| Bruttogewinn | -AU$13.79m |
| Sonstige Ausgaben | AU$11.13m |
| Umsatz | -AU$24.91m |
Zuletzt gemeldete Gewinne
Dec 31, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.017 |
| Bruttomarge | -229.04% |
| Nettogewinnspanne | -413.94% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich BNO auf lange Sicht entwickelt?
Historische Performance und Vergleiche